200 related articles for article (PubMed ID: 8823804)
21. Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy.
Goldenberg DM
Semin Nucl Med; 1989 Oct; 19(4):332-9. PubMed ID: 2678484
[TBL] [Abstract][Full Text] [Related]
22. Animal models for radiolabeled monoclonal antibodies in cancer research.
Aas M; Fjeld JG
Acta Oncol; 1993; 32(7-8):819-24. PubMed ID: 8305231
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibody based radiopharmaceuticals for imaging and therapy.
Lin M; Paolillo V; Le DB; Macapinlac H; Ravizzini GC
Curr Probl Cancer; 2021 Oct; 45(5):100796. PubMed ID: 34657748
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer.
Fleckenstein G; Osmers R; Puchta J
Med Oncol; 1998 Dec; 15(4):212-21. PubMed ID: 9951683
[TBL] [Abstract][Full Text] [Related]
26. A distributed pharmacokinetic model of two-step imaging and treatment protocols: application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin.
van Osdol WW; Sung C; Dedrick RL; Weinstein JN
J Nucl Med; 1993 Sep; 34(9):1552-64. PubMed ID: 8355076
[TBL] [Abstract][Full Text] [Related]
27. Pretargeting strategies for radio-immunoguided tumour localisation and therapy.
Stoldt HS; Aftab F; Chinol M; Paganelli G; Luca F; Testori A; Geraghty JG
Eur J Cancer; 1997 Feb; 33(2):186-92. PubMed ID: 9135486
[TBL] [Abstract][Full Text] [Related]
28. New developments in monoclonal antibodies for cancer detection and therapy.
Goldenberg DM
CA Cancer J Clin; 1994; 44(1):43-64. PubMed ID: 8281471
[TBL] [Abstract][Full Text] [Related]
29. Radiolabeled monoclonal antibodies in diagnosis and therapy of cancer. Summary and perspectives.
Britton KE
Acta Oncol; 1996; 35(3):385-90. PubMed ID: 8679271
[TBL] [Abstract][Full Text] [Related]
30. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
31. Radiolabeled antibody imaging of patients with potentially resectable colorectal adenocarcinoma.
Weiner GJ; Kahn D; Jochimsen PR; Bevering CG; Kisker MA
Cancer Invest; 1994; 12(2):111-20. PubMed ID: 8131088
[TBL] [Abstract][Full Text] [Related]
32. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies.
Zhu H; Baxter LT; Jain RK
J Nucl Med; 1997 May; 38(5):731-41. PubMed ID: 9170438
[TBL] [Abstract][Full Text] [Related]
33. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibody treatment of solid tumors: a coming of age.
Murray JL
Semin Oncol; 2000 Dec; 27(6 Suppl 11):64-70; discussion 92-100. PubMed ID: 11236030
[TBL] [Abstract][Full Text] [Related]
35. A model for others: a strategy for improving diagnosis and therapy of human malignancies using monoclonal antibodies targeting TAG-72 oncofetal antigen.
Larson SM
Cancer Invest; 1993; 11(2):235-8. PubMed ID: 8462025
[No Abstract] [Full Text] [Related]
36. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients.
Xiao J; Horst S; Hinkle G; Cao X; Kocak E; Fang J; Young D; Khazaeli M; Agnese D; Sun D; Martin E
Cancer Biother Radiopharm; 2005 Feb; 20(1):16-26. PubMed ID: 15778575
[TBL] [Abstract][Full Text] [Related]
37. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.
Brouwers AH; Buijs WC; Oosterwijk E; Boerman OC; Mala C; De Mulder PH; Corstens FH; Mulders PF; Oyen WJ
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3953S-60S. PubMed ID: 14506194
[TBL] [Abstract][Full Text] [Related]
38. Correlative imaging with monoclonal antibodies in colorectal, ovarian, and prostate cancer.
Neal CE; Meis LC
Semin Nucl Med; 1994 Oct; 24(4):272-85. PubMed ID: 7817200
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
Sharkey RM; Juweid M; Shevitz J; Behr T; Dunn R; Swayne LC; Wong GY; Blumenthal RD; Griffiths GL; Siegel JA
Cancer Res; 1995 Dec; 55(23 Suppl):5935s-5945s. PubMed ID: 7493374
[TBL] [Abstract][Full Text] [Related]
40. The current status of radiolabeled monoclonal antibodies for the diagnosis and treatment of human malignancies.
Kuzel TM; Duda RB
Compr Ther; 1992 Jun; 18(6):16-20. PubMed ID: 1511591
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
